Published on Pfizer: the world's largest research-based pharmaceutical company (http://www.pfizer.com)

Home > News & Media > Press Releases > Press Release Archive > Press Release Archive

Press Release Archive

Press Release Archive

Print Email Return to Headlines
 
May 13, 2009 - Pfizer to Present New Clinical Data Highlighting Customized Treatment Approaches For Difficult-To-Treat Cancers

(BUSINESS WIRE)--Pfizer will present new data highlighting the company’s commitment to a personalized approach to oncology clinical research, which includes the use of targeted agents in specific patient populations in several advanced and difficult-to-treat cancers. These data will be presented later this month at the 45th Annual American Society of Clinical Oncology (ASCO) annual meeting in Orlando from May 29 to June 2.

 
May 12, 2009 - Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Frank D’Amelio, Chief Financial Officer, at the 34th Annual Deutsche Bank Healthcare Conference on Tuesday, May 19, 2009 at 3:15 p.m. Eastern Daylight Saving Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Deutsche Bank Healthcare Conference” link

 
May 12, 2009 - Greg Simon, Noted Leader In Health And Science Policy, Joins Pfizer

(BUSINESS WIRE)--Pfizer Inc announced today that Greg Simon has joined the company as Senior Vice President, Worldwide Policy. He comes to Pfizer from the presidency of FasterCures, where he led efforts to reform policies governing biopharmaceutical discovery and development, with the goal of bringing a greater number of lifesaving medicines more quickly to doctors and patients. “Greg and his record of leadership are well-known

 
May 5, 2009 - Pfizer And Wisconsin Alumni Research Foundation (WARF) Sign License Agreement For Human Embryonic Stem Cells

(BUSINESS WIRE)--Pfizer, Inc (NYSE: PFE), the world's premier biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, announced today that they have signed a license for human embryonic stem (hES) cell patents for the development of new drug therapies. The WARF license provides Pfizer the rights to work

 
May 4, 2009 - Dr. Freda Lewis-Hall Joins Pfizer As Chief Medical Officer

(BUSINESS WIRE)--Pfizer Inc announced today that Freda Lewis-Hall, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Pfizer Inc. Dr. Lewis-Hall will be the senior physician in the company, responsible for enterprise-wide medical, patient safety, regulatory affairs and quality assurance as well as outreach to doctors and other medical professionals. She joins Pfizer from Vertex Pharmaceuticals, where she was

 
April 29, 2009 - Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post-Traumatic Peripheral Nerve Pain, New Data Show

(BUSINESS WIRE)--Patients suffering from post-traumatic peripheral nerve pain treated with Lyrica® (pregabalin) capsules CV experienced significantly reduced pain compared to those taking placebo, according to new data presented today at the American Academy of Neurology annual meeting. The data also showed that patients treated with Lyrica reported less pain interference with sleep and were significantly more likely to report feeling better

 
April 29, 2009 - Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Bernstein Pharmaceutical Emerging Markets Conference on Wednesday, May 6, 2009 at 8:45 a.m. Eastern Daylight Savings Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Bernstein

 
April 27, 2009 - Pfizer Reports First-Quarter 2009 Results; Reaffirms Full-Year 2009 Financial Guidance for Revenues and Adjusted Results(1)

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): ($ in millions, except per share amounts) First-Quarter 2009 2008

 
April 23, 2009 - Pfizer Supports The Global Fight Against Malaria And Commemorates World Malaria Day – “Counting Malaria Out”

(BUSINESS WIRE)--According to the World Health Organization (WHO) malaria infects approximately 250 million people per year throughout the developing world and results in a grave loss of life of at least 880,000 per year. The region most severely afflicted is Sub-Saharan Africa, but the disease is also present in Asia, Latin America, the Middle East and some parts of Europe. Pfizer recognizes the important role a pharmaceutical

 
April 23, 2009 - Pfizer And University College London Announce Collaboration To Advance Development Of Stem Cell-Based Therapies

(BUSINESS WIRE)--Pfizer Regenerative Medicine today announced that it has entered into a collaboration and license agreement with University College London focused on gaining better understanding into how to develop stem cell-based therapies for certain ophthalmic conditions. The Pfizer/UCL collaboration brings together the pioneering work of university researchers in the field of cell-based therapies and Pfizer’s

 
April 23, 2009 - Pfizer Hosts Annual Meeting Of Shareholders; Declares A 16-Cent Second-Quarter 2009 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 16-cent second-quarter 2009 dividend on the company’s common stock, payable June 2, 2009, to shareholders of record at the close of business on May 8, 2009. The second-quarter 2009 cash dividend will be the 282nd consecutive quarterly dividend paid by Pfizer. At the company’s Annual Meeting of Shareholders, Chairman and Chief Executive

 
April 22, 2009 - Pfizer and Medicines for Malaria Venture Advancing International Research Efforts in the Fight against Malaria

(BUSINESS WIRE)--NEW YORK

 
April 22, 2009 - New Findings from Global Survey of Women Living with Metastatic Breast Cancer Highlight Strategies to Improve Patient Enrollment in Clinical Trials

(BUSINESS WIRE)--Newly released findings from the BRIDGE survey (Bridging Gaps, Expanding Outreach – Metastatic Breast Cancer Patient Survey) found that most (78 percent) women living with metastatic breast cancer (MBC) have never participated in a clinical trial. Of these women, more than half (56 percent) were never invited to consider a clinical trial and one-third (30 percent) had not been recommended a clinical trial by their

 
April 20, 2009 - Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 23. To access the Webcast, visit our Web site at www.pfizer.com and click on the “Annual Meeting of Shareholders” Webcast link in the Investor Presentations tab on our homepage. Information on accessing and pre-registering for the Webcast will be

 
April 12, 2009 - Pfizer To Make A Tender Offer To Increase Stake In Pfizer Limited

(BUSINESS WIRE)--Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of Pfizer Inc, announced today that it will make a tender offer to acquire a 33.77% stake in Pfizer Limited from public shareholders at a price of Rs. 675.00 per share. Successful completion of this offer, assuming full acceptance, would raise the indirect stake of Pfizer Inc in Pfizer Limited to 75% from the current level of 41.23%. The

 
April 10, 2009 - Pfizer’s Oncology Business Unit Appoints Vice President of Medical Affairs

(BUSINESS WIRE)--Pfizer Inc announced today the appointment of Martine J. George, M.D., M.Sc, to Vice President of Medical Affairs for its Oncology Business Unit. Dr. George will be responsible for managing external relationships with cancer agencies, organizations and specialists around the world. “We are delighted that Dr. George – with her impressive record as a leader in global pharmaceutical organizations – will be

 
April 6, 2009 - Pfizer Announces Operating Structure and Select Senior Leadership Posts to Be Effective Immediately Upon Close of Wyeth Acquisition

(BUSINESS WIRE)--Pfizer (NYSE: PFE) today announced the planned leadership and organizational structure for its research and commercial operations that will become effective when the Wyeth acquisition closes. The company will establish a unique research model designed to advance the strong scientific capabilities of both Pfizer and Wyeth (NYSE: WYE) and to support the new company’s nine diverse health care businesses. At the

 
April 3, 2009 - Pfizer Receives Request for Additional Information from FTC Regarding Proposed Acquisition of Wyeth

(BUSINESS WIRE)--Pfizer (NYSE: PFE) today announced that it has received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to its previously announced proposed acquisition of Wyeth. The request for information from the FTC, often referred to as a “second request,” was anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (

 
April 3, 2009 - Pfizer Becomes The First Pharmaceutical Company To Be Accredited For Protection Of Human Rights In Clinical Research

(BUSINESS WIRE)--Pfizer Inc announced today that it has become the first pharmaceutical company to be accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for ensuring the protection of human subjects taking part in early-stage clinical trials. The AAHRPP accreditation was awarded to Pfizer’s clinical research units (CRUs) in New Haven, CT, Brussels, Belgium and Singapore, where the

 
April 2, 2009 - Pfizer Development Pipeline Shows Advances In High-Priority Disease Areas

(BUSINESS WIRE)--Pfizer Inc today provided an update to its pipeline, highlighting the progression of clinical programs in high-priority therapeutic areas, and announced the start of Phase 3 clinical trials for two new molecular entities. In total, the company initiated seven Phase 3 programs within the past six months. Earlier this year, Pfizer started Phase 3 studies in a first-in-class JAK inhibitor (CP-690,550), the first orally-

Pages

  • « first
  • ‹ previous
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • next ›
  • last »

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS. RSS Feed

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.

Printable Version
 
 

Current Stock Price

. .
.
%Change . 52 Wk. High .
Day High . 52 Wk. Low .
Day Low . Mkt. Cap(Bil) .
Open .    
Prev Close . Symbol .
Vol. . Exchange .
Cost Basis Calculator

Online Pfizer Press Kit

Our press kit provides information that might help you write stories or simply find out more about Pfizer.

  • View the Pfizer Company Press Kit

 


Source URL: http://www.pfizer.com/news/press-release/press-releases-archive?field_press_release_date_value[value]=&page=24